menu
    • menu
    [{"orgOrder":0,"company":"Cellusion","sponsor":"Hangzhou Celregen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"CLS001","moa":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Cellusion","amount2":0.10000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0.10000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Cellusion \/ Hangzhou Celregen Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Cellusion \/ Hangzhou Celregen Therapeutics"},{"orgOrder":0,"company":"Cellusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"CLS001","moa":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Cellusion","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cellusion \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cellusion \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Cellusion

    Menu

    Cellusion

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cellusion

                            Japan arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Cellusion

                            Japan arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CLS001

                            Therapeutic Area : Ophthalmology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cellusion Receives U.S. FDA Orphan Drug Designation for CLS001

                            Details : U.S. FDA has granted Orphan Drug Designation for Cellusion CLS001, a therapeutic regenerative medicine product. It is currently undergoing IND Enabling studies for the treatment of bullous keratopathy.

                            Brand Name : CLS001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            December 22, 2023

                            Lead Product(s) : CLS001

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cellusion

                            Japan arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Cellusion

                            Japan arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CLS001

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Sponsor : Hangzhou Celregen Therapeutics

                            Deal Size : $100.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Cellusion and Celregen, a member of Fosun Pharma, Enter into Exclusive License Agreement of CLS001 for a Corne...

                            Details : Under the Agreement, Celregen will have the exclusive right to develop, manufacture and commercialize CLS001 for bullous keratopathy in the Greater China region, including Mainland China, Hong Kong, Macau and Taiwan.

                            Brand Name : CLS001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 12, 2022

                            Lead Product(s) : CLS001

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Sponsor : Hangzhou Celregen Therapeutics

                            Deal Size : $100.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth